Is CYTK or DCOY more undervalued in 2026?

CirclFi compares Cytokinetics, Incorporated (CYTK) and Decoy Therapeutics Inc. (DCOY) using 13 institutional-grade valuation models. CYTK has a Quality of Company score of 5.9/10 while DCOY scores 3.7/10.

Which is a better buy — CYTK or DCOY?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CYTK and DCOY valuations compare?

CYTK at $76.81 and DCOY at $7.91 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CYTK vs DCOY Valuation Comparison 2026 — Intrinsic Value Analysis

CYTK

Biotechnology

Cytokinetics, Incorporated

Quality

5.9

out of 10

Value Trap

LOW

Price

$76.81

Last close

Models

9/13

Active

DCOY

Biotechnology

Decoy Therapeutics Inc.

Quality

3.7

out of 10

Value Trap

LOW

Price

$7.91

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	CYTK Fair Value	CYTK Upside	DCOY Fair Value	DCOY Upside
Bayesian DCF	Intrinsic	$24.22	-68.5%	$10.17	+28.5%
Earnings Power Value	Intrinsic	$21.45	-67.2%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$14.37	-81.7%	$0.72	-87.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CYTK vs DCOY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CYTK vs DCOY — Which Stock Is More Undervalued?

CYTK scores higher with a 5.9/10 quality rating vs DCOY's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cytokinetics, Incorporated (CYTK) and Decoy Therapeutics Inc. (DCOY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CYTK currently trades at $76.81 with a QOC of 5.9/10, while DCOY trades at $7.91 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).